Core Viewpoint - A class action lawsuit has been filed against POMDoctor Ltd. for allegedly engaging in a pump-and-dump scheme that defrauded investors, leading to significant losses following an initial public offering [1]. Allegations - The lawsuit claims that POMDoctor's share price increased from the IPO price of $4.00 to a peak of $6.09 without any fundamental news justifying the rise [1]. - Investigations revealed that POMDoctor used social media to promote its stock through impersonators posing as legitimate financial advisors, creating a buying frenzy among retail investors [1]. - On December 10, 2025, the share price plummeted approximately 91% to $0.50, and it has since further declined to around $0.40 [1]. Disclosure Failures - The defendants allegedly failed to disclose that POMDoctor was involved in a stock promotion scheme that relied on misinformation and impersonation [1]. - It is claimed that insiders or affiliates used offshore accounts to facilitate the coordinated selling of shares during the price inflation campaign [1]. - POMDoctor's public statements and risk disclosures reportedly omitted any mention of the false rumors and artificial trading activity affecting the stock price [1]. Shareholder Actions - Shareholders may be eligible to participate in the class action and must submit their papers to the court by April 7, 2026, if they wish to serve as lead plaintiffs [1]. - Shareholders can choose to remain absent class members without participating in the case and still be eligible for recovery [1].
POM Investors with Large Losses Should Contact Robbins LLP for Information About the POMDoctor Ltd. Securities Class Action Lawsuit